Iowa to Introduce the Sixth Comprehensive State Privacy Law in United States
Client Alert | 2 min read | 03.24.23
On March 15, the Iowa House passed Senate File 262 (SF 262), a comprehensive state privacy law bill. If enacted, SF 262 would be the sixth state level privacy legislation, following California, Virginia, Colorado, Utah, and Connecticut, and it would go into effect on January 1, 2025.
Iowa’s new law is closest to the Utah Consumer Privacy Act (UCPA), having broad exemptions and more limited obligations for controllers. Notably, SF 262 provides exemptions for consumer rights where “pseudonymous data” and “de-identified data” (as defined by the bill) are involved, including certain opt-out rights.
For the most part, Iowa’s bill treads familiar territory. Its scope extends to entities that conduct business in Iowa or produce products or services targeted to Iowa residents, and that meet the following requirements, in a calendar year: (1) control or process personal data of at least 100,000 consumers; or (2) control or process personal data of at least 25,000 consumers and derive over 50% of gross revenue from sale of personal data.
Iowa’s bill does not create new obligations for businesses compared to what is already required under other states’ privacy laws. For example, the Iowa bill’s privacy notice requirements are not unique to SF 262 – companies with privacy policies drafted to comply with the CCPA (California Consumer Privacy Act) and VCDPA (Virginia Consumer Data Protection Act) are not likely to have to amend their policies in order to comply with Iowa’s requirements. In addition, like Utah and Virginia, Iowa’s bill includes a narrow definition of “sale” of personal data (the exchange of personal data for monetary consideration by the controller to a third party), as well as numerous exceptions.
Iowa’s bill notably diverges from consumer protections found in most existing state privacy laws. For example, it only requires clear notice and opt-out for sensitive data, while other states like Colorado, Connecticut, and Virginia adopted opt-in requirements. The Iowa bill also lacks a consumer right to correct data. There are no requirements for covered entities to conduct privacy impact assessments or establish data minimization principles. Furthermore, responses to consumer requests not only have a 90-day response period (compared to 45-days in other states) but also are subject to a potential 45-day extension.
This bill does not contain a private right of action; enforcement rights belong exclusively with the Iowa State Attorney General. The AG may seek injunctive relief and civil penalties of up to $7,500 per violation. However, this first requires providing a 90-day cure period before bringing any enforcement, and such cure period does not sunset.
We will continue to monitor the developments and keep you informed of any further updates.
Contacts
Insights
Client Alert | 9 min read | 10.21.26
The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .
Client Alert | 2 min read | 10.21.26
Client Alert | 3 min read | 10.21.26
Private Investigations Act Series: Temporal, material and territorial scope
Client Alert | 7 min read | 10.21.26


